Viral Triggers

Conquering the cognitive impact of infectious disease.

The Viral Triggers team has extensive experience in virology, antiviral drug discovery, and vaccine development (Eric Arts), complex virus-host interactions of emerging viral pathogens including HIV, Ebola virus and SARS-CoV-2 (Stephen Barr); understanding how proteins move around in cells, including microglial cells, and how these processes are subverted by viruses (Jimmy Dikeakos, PhD); and zoonotic transmissions and how “new” human viruses like SARS-CoV-2 evolve and interact with their hosts to ensure viral survival and transmission (Ryan Troyer, PhD).

This team leveraging its extensive industrial collaborations to source existing antiviral and anti-inflammatory compounds that will be tested within animal models in the ImPaKT facility.